Contrasting of IDEAYA Biosciences Inc. (IDYA) and Inovio Pharmaceuticals Inc. (NASDAQ:INO)

IDEAYA Biosciences Inc. (NASDAQ:IDYA) and Inovio Pharmaceuticals Inc. (NASDAQ:INO) compete with each other in the Biotechnology sector. We will analyze and contrast their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
IDEAYA Biosciences Inc. 7 0.00 8.44M -1.96 0.00
Inovio Pharmaceuticals Inc. 2 0.00 96.30M -0.99 0.00

In table 1 we can see IDEAYA Biosciences Inc. and Inovio Pharmaceuticals Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 shows IDEAYA Biosciences Inc. and Inovio Pharmaceuticals Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
IDEAYA Biosciences Inc. 128,854,961.83% 0% 0%
Inovio Pharmaceuticals Inc. 4,052,177,572.06% -98.8% -61.3%

Liquidity

13.9 and 13.9 are the respective Current Ratio and a Quick Ratio of IDEAYA Biosciences Inc. Its rival Inovio Pharmaceuticals Inc.’s Current and Quick Ratios are 4.9 and 4.9 respectively. IDEAYA Biosciences Inc. has a better chance of clearing its pay short and long-term debts than Inovio Pharmaceuticals Inc.

Analyst Ratings

The following table delivered below contains the ratings and recommendations for IDEAYA Biosciences Inc. and Inovio Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
IDEAYA Biosciences Inc. 0 0 2 3.00
Inovio Pharmaceuticals Inc. 0 0 0 0.00

IDEAYA Biosciences Inc.’s upside potential is 179.76% at a $23.5 average price target.

Insider & Institutional Ownership

The shares of both IDEAYA Biosciences Inc. and Inovio Pharmaceuticals Inc. are owned by institutional investors at 32.5% and 44% respectively. 19.3% are IDEAYA Biosciences Inc.’s share owned by insiders. Competitively, 2.5% are Inovio Pharmaceuticals Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
IDEAYA Biosciences Inc. 4.56% -25.94% 0% 0% 0% -36.46%
Inovio Pharmaceuticals Inc. 0% -8% -25% -45.24% -32.02% -31%

For the past year IDEAYA Biosciences Inc.’s stock price has bigger decline than Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune systemÂ’s tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus. The companyÂ’s partners and collaborators include MedImmune, LLC, the Wistar Institute, University of Pennsylvania, Defense Advanced Research Projects Agency, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, the National Institutes of Health, HIV Vaccines Trial Network, National Cancer Institute, Genentech, and U.S. Military HIV Research Program. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.